Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACTOplus Met XR
- Development stage
- Phase 4
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ACTOplus Met XR is a fixed-dose combination pharmaceutical containing the thiazolidinedione pioglitazone hydrochloride and the biguanide metformin hydrochloride in an extended-release formulation. Pioglitazone is a potent and selective agonist for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), which regulates the transcription of insulin-responsive genes involved in glucose control and lipid metabolism. Metformin works primarily by decreasing hepatic glucose production and improving insulin sensitivity. While originally approved for the treatment of type 2 diabetes mellitus, this combination is being investigated by the National Cancer Institute (NCI) for its potential chemopreventive and anti-tumor effects in patients with squamous cell carcinoma of the oral cavity or oropharynx, potentially by slowing disease progression through metabolic and anti-proliferative pathways.
- Brand names
- ACTOplus Met XR
- Other names
- pioglitazone hydrochloride + metformin hydrochloride extended-releasepioglitazone + metformin XR
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on ACTOplus Met XR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACTOplus Met XR.